Movement Disorders

Elise Météreau, Maude Beaudoin-Gobert, Sandra Duperrier, Stéphane Thobois, Léon Tremblay, Véronique Sgambato-Faure October 27, 2017

ABSTRACT

Background

Diffusion tensor imaging has received major interest to highlight markers of neurodegeneration in Parkinson’s disease. Whether the alteration of diffusion parameters mostly depicts dopaminergic lesions or can also reveal serotonergic denervation remains a question.

Objectives

The aim of this study was to determine the best diffusion tensor imaging markers of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3,4-methylene-dioxy-methamphetamine (MDMA; also known as ecstasy) lesions in the nonhuman primate.

Read More...
Daniel Weintraub, Lana M. Chahine, Keith A. Hawkins, Andrew Siderowf, Shirley Eberly, David Oakes, John Seibyl, Matthew B. Stern, Kenneth Marek, Danna Jennings, October 24, 2017

ABSTRACT

Background

Prospective data on cognition in prodromal Parkinson’s disease are limited. The objectives of this study were to assess in prodromal PD (1) if baseline cognition predicts conversion to clinical PD, (2) if baseline dopamine transporter binding predicts longitudinal changes in cognition, and (3) if impaired olfaction predicts future cognitive decline.

Read More...
Sophie Fengler, Inga Liepelt-Scarfone, Kathrin Brockmann, Eva Schäffer, Daniela Berg, Elke Kalbe October 5, 2017

Abstract

Although other nonmotor phenomena representing possible prodromal symptoms of Parkinson’s disease have been described in some detail, the occurrence and characteristics of cognitive decline in this early phase of the disease are less well understood. The aim of this review is to summarize the current state of research on cognitive changes in prodromal PD.

Read More...

Andoird App
Loading...